A standardized immunosuppressive regimen for patients who received liver transplantations treated with atezolizumab-bevacizumab to avoid graft rejection?

Liver Transpl. 2022 Jul;28(7):1262-1263. doi: 10.1002/lt.26475. Epub 2022 May 24.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Bevacizumab / adverse effects
  • Graft Rejection* / prevention & control
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Liver Transplantation* / adverse effects

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Bevacizumab
  • atezolizumab